Metraipolis › archive › dc_c56e34f655cd

Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease — Europe PMC PMID:42292846

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42292846
DOI
10.3389/fphar.2026.1783414
License (as archived)
solo-consultazione
Archived
2026-11-01T05:22:43.175Z
SHA-256 of the archived text
0b6a906ae38387a040ce9f80523b7753f4f8611ac08fa801443656e6f4dec549
Stable URL of this page
https://metraipolis.com/documento/dc_c56e34f655cd

How to cite

Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease — Europe PMC PMID:42292846 — Europe PMC (en), https://europepmc.org/article/MED/42292846 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c56e34f655cd (Metraipolis archive dc_c56e34f655cd, sha256 0b6a906ae38387a040ce9f80523b7753f4f8611ac08fa801443656e6f4dec549)
BibTeX
@misc{dcc56e34f655cd,
  title = {Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease — Europe PMC PMID:42292846},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42292846},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c56e34f655cd; sha256 0b6a906ae38387a040ce9f80523b7753f4f8611ac08fa801443656e6f4dec549},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42292846. Agents can read the archived copy with the MCP tool read_document.